| Faculty (Department Wise)+ |
|---|
| ----------------------------- |
| Chemical Sciences > |
| Pharmaceutical Analysis > |
| Biological Sciences > |
| Pharmaceutics > |
| Pharmaceutical Management > |
| Medical Devics > |
| Natural Products > |
| Regulatory Affairs > |
| Pharmacoinformatics > |
| ----------------------------- |
| Young Scientists > |
| Guest Faculty > |
| ----------------------------- |
| Staff + |
| ----------------------------- |
| Technical Staff > |
| Administrative Staff > |
Prof. Nagula Shankaraiah is an accomplished medicinal and synthetic organic chemist with a distinguished record in academics and research. Over the course of his career, he has led numerous research programs focused on the rational design and synthesis of novel chemical entities (NCEs), inspired from both natural and privileged scaffolds as anti-cancer agents. He has made notable contributions for the development of cytotoxic agents targeting critical cancer pathways, including epigenetic regulators and multi-kinase inhibition, tubulin, and topoisomerase II, dual target inhibition such as VEGFR-2, CDKs, HDACs. His research encompasses aspects of modern drug discovery, including structure–activity relationship (SAR) elucidation, hit identification, hit-to-lead progression, and lead optimization. In addition to his expertise in medicinal chemistry, he is also highly proficient in the development of synthetic methodologies. His work integrates sustainable and green chemistry principles, employing state-of-the-art techniques such as click chemistry, one-pot domino transformations, and C–H activation/functionalization. He has also contributed to mechanistic organic chemistry by live ESI/MS and NMR studies. His scientific contributions are reflected in an extensive portfolio of high-impact publications and patents, underscoring his enduring impact in the field of medicinal and organic chemistry.
Full Profile
Accomplished Medicinal, Synthetic and Natural Product Organic Chemist with 30 years of industrial and academic research experience. Associated with the Indian Pharma, CRO and reputed academic institutions viz., Dr Reddy's Laboratories, Aurigene Discovery Technologies Ltd., Biocon BMS Research Centre, Albany Molecular Research, Sri Sathya Sai Institute of Higher Learning and National Institute of Pharmaceutical Education & Research, Hyderabad in various positions and roles of scientific and managerial responsibilities. Led several integrated drug discovery programs encompassing all stages of drug discovery viz., Hit generation, Hit to Lead and Lead optimization involving both Natural Product and Synthetic products in the areas of oncology, metabolic disorders, and infectious diseases. The programs carried out include both internal programs and collaborative research programs with several pharmaceutical companies/Institutes. While some of the programs have successfully transitioned to the late Lead Optimization stages (pre-clinical/clinical), one of the programs has led to a Phase 2 clinical candidate. Experienced in leading cross-functional teams which include Medicinal Chemistry, biochemistry, pharmacology, DMPK and toxicology. Several patents/publications have been filed/published.
Full Profile
Her area of research interest is synthesis of biologically active molecules. She has worked on the total synthesis of Cyclamenol-A an anti-inflammatory agent isolated from streptomyces species. It is a polyene macrolactum with seven double bonds of which only one is cis and the rest are trans double bonds. She has also worked on the development of some novel methodologies using Yb(OTf)3 , montmorillonite clay etc.
Full Profile
Dr. Priyanka Bajaj’s group has particular interest in green chemistry to make our pharmaceutical and fine chemical industry and industrial products more environmentally friendly and affordable for everyone. Her research mainly focuses on developing green biocatalytic processes and enzymes for complex synthetic chemistry challenges mainly focusing on synthesis of chiral compounds of pharmaceutical importance. The enzymes are studied in detail for their structure activity relationship and engineered using the techniques of directed evolution. The libraries of various substrates and enzymes are further screened in high throughput mode using LC/MS, GC/MS and UV-Vis spectrophotometry and upscale and downscale processes are optimized. The group is working on exploring wide range of enzymes including Aldehyde dehydrogenases (ALDHs), Myoglobin, P450s and others.
Her Research Interest includes the below
Dr. Kaki Venkata Rao’s research team primarily focuses on the discovery of novel anti-inflammatory and anti-proliferative agents through both synthetic and computational approaches. Novel selenated heterocycles, such as selenazolines and quinolines, are currently being investigated as potential kinase and MMP-9 inhibitors. The team has also developed new synthetic methodologies to produce these bioactive compounds. Additionally, efforts are underway to scale up the production of active pharmaceutical ingredients (APIs), including Melitracin and other compounds synthesized via Grignard reactions. Furthermore, the team is exploring the development of anti-inflammatory formulations based on natural product extracts from medicinal plants.
Full Profile
Dr. Sai Sudhir's research team
Full Profile